| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOE |
| Uniprot No | P02649 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-317aa |
| 氨基酸序列 | MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APOE重组蛋白的3篇参考文献摘要(文献信息为示例性内容，实际引用请核实原文)：
1. **文献名称**: "Apolipoprotein E: structure and function in lipid metabolism"
**作者**: Huang Y, Mahley RW
**摘要**: 该综述详细阐述了APOE蛋白的三维结构及其在脂蛋白代谢中的关键作用，重点讨论了重组APOE蛋白在体外结合低密度脂蛋白受体(LDLR)的机制及其对胆固醇转运的影响。
2. **文献名称**: "Recombinant human apolipoprotein E enhances Aβ clearance and reduces amyloid plaques in a mouse model of Alzheimer's disease"
**作者**: Dong J, Peters-Libeu CA, Weisgraber KH
**摘要**: 研究通过表达重组人源APOE蛋白，证明其能促进β淀粉样蛋白(Aβ)的清除，并显著减少阿尔茨海默病模型小鼠脑内的淀粉样斑块沉积，提示APOE重组蛋白在神经退行性疾病治疗中的潜力。
3. **文献名称**: "Production and characterization of recombinant human apolipoprotein E3 in Escherichia coli"
**作者**: Riddell DR, Owen JS
**摘要**: 该文献报道了利用大肠杆菌表达系统高效制备重组人APOE3蛋白的方法，通过优化纯化工艺获得高纯度蛋白，并验证其与脂质结合及调控高密度脂蛋白(HDL)代谢的功能活性。
4. **文献名称**: "APOE isoform-specific differences in tertiary structure and interaction with amyloid-β"
**作者**: Zhao L, et al.
**摘要**: 通过比较重组表达的APOE2、E3、E4亚型，揭示了不同异构体在空间构象上的差异，并证明APOE4与β淀粉样蛋白的异常结合可能加剧神经毒性，为阿尔茨海默病的分子机制提供了新见解。
Apolipoprotein E (APOE) is a lipid-binding protein crucial for lipid transport and metabolism, primarily synthesized in the liver and brain. It mediates the clearance of lipoprotein particles by binding to cell surface receptors, such as the LDL receptor family, facilitating cholesterol redistribution. Humans possess three major APOE isoforms—E2. E3. and E4—encoded by corresponding alleles. APOE3 is the most common, while APOE4 is a well-established genetic risk factor for late-onset Alzheimer’s disease (AD) and cardiovascular disorders. APOE2. in contrast, is associated with reduced AD risk but may contribute to type III hyperlipoproteinemia.
Recombinant APOE proteins are engineered in vitro using expression systems like bacteria, yeast, or mammalian cells. These systems enable large-scale production of purified APOE variants for research and therapeutic applications. For instance, recombinant APOE4 is widely used to study its pathological role in AD, including amyloid-beta aggregation, neuroinflammation, and tau phosphorylation. Conversely, recombinant APOE2 is explored for potential therapeutic benefits due to its neuroprotective properties.
In drug development, recombinant APOE serves as a tool to investigate lipid nanoparticle formulations for targeted drug delivery, leveraging its natural role in lipoprotein transport. It also aids in designing gene therapies aimed at modulating APOE expression in neurodegenerative diseases. Structural studies using recombinant proteins have elucidated isoform-specific differences in lipid-binding capacity and receptor interactions, providing mechanistic insights into disease pathways. Despite challenges in maintaining proper folding and post-translational modifications during production, advances in protein engineering continue to enhance the functional fidelity of recombinant APOE, solidifying its importance in biomedical research and therapeutic innovation.
×
